Trial Profile
Phase II Study of Consolidation Immunotherapy With Nivolumab and Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC): BTCRC-LUN16-081
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Durvalumab
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 25 Sep 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 25 Sep 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Dec 2023.
- 06 Jun 2023 Results of retrospective analysis assessing the association between immune-related adverse events and efficacy outcomes presented at the 59th Annual Meeting of the American Society of Clinical Oncology.